Clinical research is now easier with Florence Healthcare, with 80% of US residents living within 25 miles of a Florence-equipped site
ATLANTA–Florence Healthcare, the industry leader in digital workflows for clinical trials, announced today that 285 million Americans–80 percent of the U.S. population–now live within 25-miles of a Florence digital-workflow-equipped clinical research site.
According to Blake Adams, SVP of Marketing at Florence, more than 4,000 new investigator teams were added to the Florence workflow platform in 2021, bringing the total to more than 10,000 sites in 45 countries.
A person’s distance to a site conducting a study is one of the most important factors that influences their willingness to participate, impacting recruitment, enrollment, and the diversity of trials as well as the speed at which new therapies and medical advancements reach patients. Data shows 70 percent of potential clinical research participants live more than two hours away from the nearest center conducting that study.
“Traditional clinical operations models that rely on paper, on-site visits, and disruptive software portals make it difficult for sponsors to partner with sites near patients,” says Adams. “From the beginning, we believed expanding patient access required providing the best workflow technology to sites. It’s clear that the industry has embraced this approach from the velocity of sites added and the 3 million remote workflows that take place every month on our platform.”
According to Florence Chief Clinical Trial Officer, Catherine Gregor, MBA, CCRC, CCRP, in an era when patient-centered research is widely discussed and the industry is exploring new research models, such as decentralized trials, the role of the trial site remains critical. Research sponsors who change how they collaborate with sites to take advantage of remote, always-on workflows reduce the factor of physical distance by expanding their network of sites geographically.
“An expanded digital investigator network benefits both research sites and sponsors and underscores the important role technology plays in advancing cures,” says Gregor. “Sponsors are seeking sites with strong digital capabilities to support the increased emphasis on decentralized trial designs, and sites are seeking technology solutions that are reflective of their workflows. With the implementation of Florence, research sites and sponsors can find common ground in a single solution, allowing them to spend less time resolving administrative friction and more time focusing on accelerating cures and expanding patient access to trials.”
Florence is on track to double the number of investigator teams connected to its platform by the end of 2022 as part of its commitment to create the best possible study experience for sites. Florence will also continue to work with sponsors to adapt their workflows and protocols to this new model of always-on, remote access.
POWERED BY FLORENCE
Florence Healthcare streamlines clinical trials with software that enables always-on, remote workflows between research sites and sponsors. Installed as the Electronic Investigator Site File at over 10,000 study sites in 45 countries, Florence supports more than 3 million remote workflows every month. To learn more, visit florencehc.com.
